Virios therapeutics announces halt to at-the-market offering sales

Atlanta, aug. 14, 2023 (globe newswire) -- virios therapeutics, inc. (nasdaq: viri) (the “company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases such as fibromyalgia (“fm”) and long-covid, today announced that it has advised its sales agent, jonestrading institutional services llc (“jonestrading”), to cease sales under the capital on demandtm sales agreement entered into between the company and jonestrading on july 14, 2023.
VIRI Ratings Summary
VIRI Quant Ranking